Breast Thermography Has Poor Diagnostic Performance and Should Not Be Used for Breast Cancer Detection
Thermography is not recommended for breast cancer screening or detection and should not replace or supplement mammography. The established screening modalities—mammography, clinical breast examination (CBE), and MRI (in high-risk populations)—have proven mortality reduction benefits, while thermography lacks this evidence 1.
Diagnostic Accuracy: Thermography vs. Established Modalities
Established Screening Methods (from Guidelines)
The USPSTF guidelines clearly define the performance characteristics of validated screening methods 1:
- Mammography: Sensitivity 77-95%, Specificity 94-97%
- MRI (high-risk women): Sensitivity 71-100%, Specificity 81-97%
- Clinical Breast Examination: Sensitivity 40-69%, Specificity 88-99%
- Breast Self-Examination: Sensitivity 12-41% (age-dependent)
Thermography Performance (from Research Studies)
The research evidence shows highly variable and generally inferior performance:
- Most recent study (2026): Sensitivity 69%, Specificity 63% 2
- 2026 comparative study: Detected 18 of 24 malignant lesions (75% sensitivity), with AUC 0.875 3
- 2020 prospective study: Sensitivity 82% in women <50 years, 78% in women ≥50 years; Specificity 87% in younger women but only 60% in older women 4
- 2018 comparative study: Sensitivity 85.7%, Specificity 78.5%, PPV only 15.8% 5
- 2016 Chinese study: Sensitivity 83.33%, Specificity 83.16% 6
- 2014 Indian pilot study: Claimed sensitivity 97.6%, specificity 99.17%, but this outlier study had significant methodological concerns 7
Critical Limitations of Thermography
Why Thermography Fails as a Screening Tool
No mortality reduction data: Unlike mammography, which demonstrates relative risk reduction of 0.85-0.86 for women aged 39-59 years and 0.68 for women aged 60-69 years 1, thermography has never been studied in randomized controlled trials for mortality outcomes.
Extremely low positive predictive value: Even in the most favorable studies, thermography's PPV ranges from 15.8% to 50% 4, 5, meaning the vast majority of positive results are false positives. This leads to unnecessary anxiety, additional testing, and biopsies.
Inconsistent performance across age groups: Specificity drops dramatically in women ≥50 years (60% vs 87% in younger women) 4, precisely the population at highest risk for breast cancer.
High false-positive rates: Studies show false-positive rates that would overwhelm clinical resources if used for population screening 4, 5.
Lack of standardization: No standardized protocols exist for image acquisition, interpretation, or temperature thresholds. Cutoff points vary widely across studies (≥2.5°C, ≥3°C, ≥33.4°C) 7, 2.
Regulatory Position
The FDA explicitly states that thermography should not be used in place of mammography for breast cancer screening or diagnosis 8. This is a critical regulatory warning that clinicians must heed.
Clinical Implications
What to Tell Patients
When patients inquire about thermography:
- Explain that mammography is the only screening method proven to reduce breast cancer mortality 1
- Clarify that thermography's sensitivity (ability to detect cancer) is substantially lower than mammography
- Emphasize that a negative thermogram does not rule out breast cancer
- Note that thermography generates many false-positive results, leading to unnecessary worry and testing
Appropriate Screening Recommendations
Based on the most recent ACP guidance (2026) 9:
- Ages 40-49: Shared decision-making discussion, then biennial mammography if patient prefers screening
- Ages 50-74: Biennial mammography for all average-risk women
- Age 75+: Discuss discontinuation based on life expectancy and patient preferences
- Dense breasts (BI-RADS C or D): Consider supplemental digital breast tomosynthesis; do NOT use supplemental MRI or ultrasound in average-risk women 9
High-Risk Women
For women at elevated risk (BRCA mutations, strong family history), MRI is recommended as an adjunct to mammography starting at age 30, with sensitivity 71-100% and specificity 81-97% 1, 10, 1. Thermography has no role in this population.
Common Pitfalls to Avoid
- Do not order thermography as a "radiation-free alternative" to mammography—this delays appropriate screening and may miss cancers
- Do not use thermography in women with dense breasts—despite marketing claims, no evidence supports superior performance in this population 8
- Do not reassure patients with negative thermograms—the false-negative rate is unacceptably high
- Do not order thermography "just to see"—positive results will require standard imaging anyway, adding cost and anxiety without benefit
Bottom Line
Thermography lacks the sensitivity, specificity, standardization, and most importantly, mortality reduction data necessary for breast cancer screening. Mammography remains the gold standard for average-risk women, with proven mortality benefit across multiple age groups 1. The most recent evidence (2026) continues to show thermography's inferior performance 3, 2, 8, 9, and regulatory agencies explicitly warn against its use as a screening tool 8.